E
ESMO 2014 Bladder Cancer

Breathing New Life into Bladder Cancer Treatment

At ESMO 2014, phase 1 clinical trial data in bladder cancer was presented for Pembrolizumab (Merck) and MPDL3280A (Roche/Genentech).

October 22, 2014
E
Roche Media Briefing ESMO 2014

Potential of IDO as Immunotherapy Target

Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?

October 20, 2014
E
ESMO 2014 E Posters

ESMO 2014 Cancer Congress Day 3 Live Blog

Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.

September 28, 2014
E
ESMO 2014 Congress Madrid

ESMO 2014 Live Blog Day 2 #ESMO14

Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid

September 28, 2014
E
Roche Promise of Immunotherapy Quote

ESMO 2014 Cancer Congress Day 1 Live Blog

ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.

September 27, 2014
E
Air France Concorde Paris CDG

ESMO 2014 Takes Off with Release of Oral Abstracts #ESMO14

Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.

September 24, 2014
E
Do not feed the Pelicans

ESMO 2014 Scientific Symposia Preview

There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.

September 19, 2014
E
St Pancras International

ESMO 2014 Poster Preview

A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014

September 18, 2014
E
Tall Ship Pageant

ESMO 2014 Preview: Immuno-oncology

Update on what to watch out for in immunotherapy at ESMO 2014.

September 16, 2014
E
Antoni Ribas ASCO 2014 Melanoma

What impact will nivolumab & pembrolizumab have on advanced melanoma?

How will we decide which therapies to give patients with metastatic melanoma once the new immunotherapies are available?

July 23, 2014
E
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014
E
Kite Pharma Banner

Kite Pharma Challenges and Opportunities Post-IPO $KITE

After it's successful IPO, what are some of the challenges and opportunities facing Kite Pharma and their CAR-T cell immunotherapy?

June 23, 2014
E
ASCO 2014 Crowds

AstraZeneca MEDI4736 shows Immuno-Oncology promise at ASCO 2014

AstraZeneca showed impressive data at ASCO 2014 for MEDI4736, a new anti PD-L1 immunotherapy.

June 19, 2014
E
Chicago Board of Trade Building

Making a difference in advanced bladder cancer

There have been no new therapies in urothelial bladder cancer for 30 years - until now...

June 17, 2014
E
Chicago Art Institute

ASCO 2014 Nivolumab vs Pembrolizumab in Metastatic Melanoma

PD-1 antibodies nivolumab and pembrolizumab show considerable promise in metastatic melanoma. At ASCO 2014 we learnt more about how they compare against each other and their potential as a backbone for combinations.

June 16, 2014
E
ASCO 2014 Chicago the Bean

Combination strategies for nivolumab in Renal Cell Carcinoma

What does the ASCO 2014 data show when you combine checkpoint inhibitors nivolumab and ipilimumab?

June 13, 2014
E
T cell immunotherapy

6 important things I learned from AACR 2014 on immuno-oncology

Insights on checkpoint inhibitors, co-stimulants, CAR T cell therapy and bispecific antibody TCRs

May 2, 2014
E
AACR San Diego

New directions in immuno-oncology in biomarkers and combinations

Update on emerging potential immuno-oncology biomarkers and combinations from AACR

April 30, 2014
E
MSKCC Trial Suspensions

The real story behind Juno’s CAR T cell therapy suspensions

This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.

April 6, 2014
E
Screenshot 2014-04-02 13.29.39

Innate immunotherapy – is it ready for prime time in cancer research?

A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.

April 2, 2014
E
Source: James Kochendefer, NCI

Will CAR T cells give new therapies for NHL and CLL a run for their money?

Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas

March 6, 2014
E
Anti-CTLA-4 ipilimumab

Update on immuno-oncology and biomarkers of response

ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.

February 5, 2014
E
Screenshot 2014-02-04 15.14.55

ASCO GU 2014 Optimal targeting of anti PD-1 and PD-L1 therapies in renal cancer

Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?

February 4, 2014
E
Source: Roche

Update on anti-PD-L1 cancer immunotherapy

Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?

January 22, 2014
E
Title Slide ASCO GI Keynote

ASCO GI Keynote: The future of Immunotherapy is Combinations

“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.

January 21, 2014
E
CAR T Cells

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014
E
Screen Shot 2014-01-07 at 11.22.26 AM

New Immunotherapy data at IASLC Lung Cancer Meeting

Immunotherapy continues to be a hot topic in oncology with anti-PD-1 and other new approaches being discussed at the AACR-IASLC meeting in San Diego

January 7, 2014
E
St Jude Penn Legal Case Citation

Juno Therapeutics takes on Penn in dispute over St Jude Chimeric Antigen Receptor Patent

Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.

January 6, 2014
E
Renier Brentjens ASH 2013 Disclosure

Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens

Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.

December 13, 2013
E
KIR Occupancy by IPH2101

Will anti-KIR immunotherapy make an impact in hematologic malignancies?

Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.

December 12, 2013
E
Brentjens CART Slide

ASH 2013 Preview: will new Seattle startup Juno Therapeutics push Novartis and U Penn in CART?

Chimeric Antigen Receptor T cell technology (CART) is an exciting new area, especially in hematologic malignancies. With the formation of a new start-up in Seattle, Juno Therapeutics, things just got very interesting...

December 4, 2013
E
Fall Colors Boston

New insights on checkpoint inhibitors and CART in CLL and solid tumors

An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!

October 25, 2013
E
IMG_8574

ECCO Day 3: Update on alectinib, PD-L1, PI3K and MEK

Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours

September 30, 2013
E
ECCO 2013 Conference Amsterdam

A top line look at the PD-1 and PD-L1 abstracts at ECCO 2013

A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.

September 19, 2013
E
With permission from Dr Wolchok

How new approaches in targeted immunotherapy with anti-PD-1 and PD-L1 may change cancer research

Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.

September 18, 2013
E
ASH 2012 Ernest Beutler Lecture

ASH 2012: CTL019 chimeric antigen receptor technology emerging as a new leukemia treatment

For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

January 15, 2013